and HGMD to improve identification and interpretation of genetic variants within inherited diseases.
QIAGEN has launched a "Digital Insights Partnership" program designed to expand the market for its bioinformatics products through various third-party collaborations and deals.
The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina’s MiSeq™ Dx and NextSeq™ 550Dx Systems
QCI, a clinical decision support platform for interpretation and reporting of variants derived from analysis of next-generation sequencing (NGS) data, has achieved a milestone of more than 1 million patient test cases analyzed and interpreted
A new initiative to help address the global crisis of antibiotic-resistant pathogens. ...
Japan’s Center for Cancer Genomics and Advanced Therapeutics (C-CAT), a unit within the National Cancer Center (NCC) of Japan ...
Genomics England have extended the contract for QIAGEN’s HGMD® Human Gene Mutation Database offering on behalf of the NHS in England.